Vantavo (previously Alendronate sodium and colecalciferol, MSD) الاتحاد الأوروبي - الأيسلاندية - EMA (European Medicines Agency)

vantavo (previously alendronate sodium and colecalciferol, msd)

n.v. organon - alendronic sýru, colecalciferol - beinþynning, eftir tíðahvörf - lyf til að meðhöndla beinsjúkdóma - meðferð við beinþynningu eftir tíðahvörf hjá sjúklingum í hættu á d-vítamínskorti. vantavo dregur úr hættu hryggjarliðum og mjöðm beinbrot. meðferð tíðahvörf beinbrot í sjúklingum sem eru ekki fá vítamín-d viðbót og eru í hættu á d-d lungnastarfsemi. vantavo dregur úr hættu hryggjarliðum og mjöðm beinbrot.

Candpress Comp Tafla 16 mg/12,5 mg أيسلندا - الأيسلاندية - LYFJASTOFNUN (Icelandic Medicines Agency)

candpress comp tafla 16 mg/12,5 mg

teva b.v.* - candesartanum cílexetíl; hydrochlorothiazide - tafla - 16 mg/12,5 mg

Valsartan/Hydrochlorothiazide Krka Filmuhúðuð tafla 160 mg/12,5 mg أيسلندا - الأيسلاندية - LYFJASTOFNUN (Icelandic Medicines Agency)

valsartan/hydrochlorothiazide krka filmuhúðuð tafla 160 mg/12,5 mg

krka sverige ab - hydrochlorothiazide; valsartanum inn - filmuhúðuð tafla - 160 mg/12,5 mg

Valsartan/Hydrochlorothiazide Krka Filmuhúðuð tafla 160 mg/25 mg أيسلندا - الأيسلاندية - LYFJASTOFNUN (Icelandic Medicines Agency)

valsartan/hydrochlorothiazide krka filmuhúðuð tafla 160 mg/25 mg

krka sverige ab - hydrochlorothiazide; valsartanum inn - filmuhúðuð tafla - 160 mg/25 mg

Valsartan/Hydrochlorothiazide Krka Filmuhúðuð tafla 80 mg/12,5 mg أيسلندا - الأيسلاندية - LYFJASTOFNUN (Icelandic Medicines Agency)

valsartan/hydrochlorothiazide krka filmuhúðuð tafla 80 mg/12,5 mg

krka sverige ab - valsartanum inn; hydrochlorothiazide - filmuhúðuð tafla - 80 mg/12,5 mg

Valsartan/Hydroklortiazid Jubilant Filmuhúðuð tafla 160 mg/ 12.5 mg أيسلندا - الأيسلاندية - LYFJASTOFNUN (Icelandic Medicines Agency)

valsartan/hydroklortiazid jubilant filmuhúðuð tafla 160 mg/ 12.5 mg

jubilant pharmaceuticals nv - valsartanum inn; hydrochlorothiazidum inn - filmuhúðuð tafla - 160 mg/ 12.5 mg

Cabometyx الاتحاد الأوروبي - الأيسلاندية - EMA (European Medicines Agency)

cabometyx

ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - Æxlishemjandi lyf - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.

Zarator Filmuhúðuð tafla 80 mg أيسلندا - الأيسلاندية - LYFJASTOFNUN (Icelandic Medicines Agency)

zarator filmuhúðuð tafla 80 mg

upjohn eesv - atorvastatin calcium - filmuhúðuð tafla - 80 mg

Zarator Filmuhúðuð tafla 40 mg أيسلندا - الأيسلاندية - LYFJASTOFNUN (Icelandic Medicines Agency)

zarator filmuhúðuð tafla 40 mg

upjohn eesv - atorvastatin calcium - filmuhúðuð tafla - 40 mg

Zarator Filmuhúðuð tafla 20 mg أيسلندا - الأيسلاندية - LYFJASTOFNUN (Icelandic Medicines Agency)

zarator filmuhúðuð tafla 20 mg

upjohn eesv - atorvastatin calcium - filmuhúðuð tafla - 20 mg